MNOV, US58468P2065

MediciNova reports mixed trial data as analysts rate MediciNova stock

Published on 10/14/2026 at 05:48 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

MediciNova's Phase 2 study enrolled 40 patients and missed primary endpoints on October 12, 2026. Four of seven analysts rate MediciNova stock Buy.

Clinical milestones and analyst views

On October 12, 2026, MediciNova updated investors after a 40-patient Phase 2 trial.
COMBAT-ALS enrolled 234 participants in its double-blind portion.
MediciNova expects its next earnings report on November 12, 2026.
Four of seven analysts rate the stock Buy, according to MarketBeat on October 9, 2026.

MNOV, US58468P2065, Illustration mit AI erstellt.

MediciNova reported mixed Phase 2 findings on October 12, 2026, while MarketBeat said on October 9, 2026, that four of seven analysts rated MediciNova stock Buy. The company is now balancing encouraging biomarker signals against a trial that missed its primary endpoints.

Three clinical milestones

On September 24, 2026, MediciNova announced the last patient visit in the double-blind portion of COMBAT-ALS, a Phase 2b/3 trial with 234 participants. Topline results from that portion are expected by the end of 2026.

On September 28, 2026, Finanznachrichten published the company's topline results from the 40-patient MN-001 study. The 24-week trial compared tipelukast with placebo in patients with nonalcoholic fatty liver disease and elevated triglycerides linked to type 2 diabetes.

On October 12, 2026, GlobeNewswire reported that the MN-001 study did not achieve statistical significance on its primary endpoints. MediciNova said HDL cholesterol, HDL particle concentration and an early triglyceride measure improved significantly versus placebo, while later reductions in triglycerides, liver fat and body weight did not reach statistical significance.

What does the mixed trial mean

The result leaves MN-001 in a development phase rather than creating a clear efficacy milestone. MediciNova said it was conducting further analysis of the full dataset, including the influence of concomitant medication and baseline lipid severity.

The company also reported no drug-related serious adverse events in the study. That safety result supports additional assessment, but the 40-patient sample and the failed primary endpoints keep the next development step dependent on the ongoing analysis.

ALS results set the next date

MediciNova's nearer-term market test is COMBAT-ALS. The trial's primary endpoint combines function and survival, and the company expects topline results by the end of 2026; the final patient visit for the full study is expected in March 2027, according to the September 24, 2026 release.

Investing.com lists November 12, 2026, as the next earnings date. MarketBeat also reported an average 12-month analyst target of USD 7.75 on October 9, 2026, alongside four Buy ratings, one Strong Buy rating, one Hold rating and one Sell rating.

Market value and pipeline risk

MediciNova had a market capitalization of USD 73.8 million as of October 13, 2026. Its 52-week range was USD 1.17 to USD 3.90, underscoring the valuation sensitivity to clinical readouts while the company advances MN-166 and MN-001.